Valiant Laborato (VALIANTLAB)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low leverage with Debt/Equity of 0.17, balance sheet is not burdened
• High promoter holding of 74.94% aligns management with minority shareholders
• Top-line momentum: sales growth of 48.91% and latest quarterly sales of ₹52 Cr
• Tangible book value of ₹42.32 per share provides some downside reference

Concerns

• Latest quarter net loss of ₹7 Cr and profit growth of -400.43% mean no earnings to value
• ROE of only 2.29% and negative ROCE of -0.95% indicate poor capital efficiency
• Piotroski F-Score of 3/9 suggests weak financial health
• No dividend and negative profitability offer no return to shareholders today

AI Analysis

At ₹75.59, Valiant Laborato has a market cap of ₹311 Cr, but I struggle to call it a business just yet. A P/E of zero and a latest quarter net loss of ₹7 Cr on sales of ₹52 Cr tell me there are no earnings to support the price. Sales growth of 48.91% is eye-catching, but profit growth of -400.43% shows that the growth is unprofitable. In my experience, revenue without profit is merely a claim on future capital, not a record of value creation. The firm earns only 2.29% ROE and a negative ROCE of -0.95%, meaning it is destroying, not creating, shareholder value relative to capital employed. On the Graham side, book value is ₹42.32; buying at ₹75.59 means paying 1.79 times book for a subpar return stream. That leaves little margin of safety. I do see one Graham-like positive: debt/equity of 0.17, so the balance sheet is not stretched, and promoter holding of 74.94% aligns ownership with public shareholders. But no dividend, a Piotroski score of 3/9, and deteriorating profitability offset those positives. This is not a compounder or stalwart. It may be an early-stage turnaround, but only if management can convert sales growth into real operating profits. Until I see positive earnings, positive ROCE, and cash flow that supports reinvestment, I would watch from the sidelines. The numbers are in the fields, not in the future; there is no story to calculate. I need evidence of margin recovery before I would ever consider investing any of my own money.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer